@article {Choi:2017:0008-4212:129,
title = "Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice",
journal = "Canadian Journal of Physiology and Pharmacology",
parent_itemid = "infobike://cndscipub/cjpp",
publishercode ="cndscipub",
year = "2017",
volume = "95",
number = "2",
publication date ="2017-01-01T00:00:00",
pages = "129-139",
itemtype = "ARTICLE",
issn = "0008-4212",
eissn = "1205-7541",
url = "https://www.ingentaconnect.com/content/cndscipub/cjpp/2017/00000095/00000002/art00004",
doi = "doi:10.1139/cjpp-2016-0026",
keyword = "oxidative stress, protéine kinase dépendante de l’AMP, inflammation adipeuse, adipocyte hypertrophy, DPP-4 inhibitor, régime alimentaire occidental, nonalcoholic steatohepatitis, adipose inflammation, Western diet, stéatose hépatique non alcoolique, inhibiteur de la DPP-4, metabolic syndrome, AMP-dependent protein kinase, hypertrophie des adipocytes, stress oxydant, syndrome métabolique",
author = "Choi, Seung Hee and Leem, Jaechan and Park, Sungmi and Lee, Chong-Kee and Park, Keun-Gyu and Lee, In-Kyu",
abstract = "Dipeptidyl peptidase 4 (DPP-4) inhibitors are widely used antihyperglycemic agents for type 2 diabetes mellitus. Recently, increasing attention has been focused on the pleiotropic actions of DPP-4 inhibitors. The aim of the present study was to examine whether gemigliptin, a recently
developed DPP-4 inhibitor, could ameliorate features of metabolic syndrome. Mice were fed a Western diet (WD) for 12 weeks and were subsequently divided into 2 groups: mice fed a WD diet alone or mice fed a WD diet supplemented with gemigliptin for an additional 4 weeks. Gemigliptin treatment
attenuated WD-induced body mass gain, hypercholesterolemia, adipocyte hypertrophy, and macrophage infiltration into adipose tissue, which were accompanied by an increased expression of uncoupling protein 1 in subcutaneous fat. These events contributed to improved insulin sensitivity, as assessed
by the homeostasis model assessment of insulin resistance and intraperitoneal insulin tolerance test. Furthermore, gemigliptin reduced WD-induced hepatic triglyceride accumulation via inhibition of de novo lipogenesis and activation of fatty acid oxidation, which was accompanied by AMP-dependent
protein kinase activation. Gemigliptin ameliorated WD-induced hepatic inflammation and fibrosis through suppression of oxidative stress. These results suggest that DPP-4 inhibitors may represent promising therapeutic agents for metabolic syndrome beyond their current role as antihyperglycemic
agents.",
}